Clinical trials: Clopidogrel, completed
Ischemic Cerebrovascular Accident
Clopidogrel for Acute Ischaemia of Recent Onset
Evaluate the role of loading Clopidogrel in acute ischemic stroke in improving neurological outcome of stroke in cases patients will be non-eligible for, or declined, treatment with or intravenous thrombolysis with rTPA, rTPA is…
- Trial name
- CAIRO (NCT02776540)
- Testing
- Clopidogrel, Aspirin
- Where
- Egypt
- Volunteers
- 188 people
- Sponsor
- Ain Shams University
Acute Coronary Syndromes
PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
The investigators hypothesize that reduced loading dose of prasugrel followed by reduced maintenance dose of prasugrel in acute coronary syndrome patients with CYP2C19 polymorphism undergoing percutaneous coronary intervention…
- Trial name
- PRAISE-GENE (NCT01641510)
- Testing
- Prasugrel, Clopidogrel
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- Dong-A University
Acute Coronary Syndrome
Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent
Background: The optimal duration of dual antiplatelet therapy in ACS patients treated with DES is still under debate. This is especially true for STEMI patients in the era of new anticoagulants and antiplatelet agents.
- Trial name
- REDUCE (NCT02118870)
- Testing
- Treatment 90 days DAPT, Treatment 360 days DAPT
- Volunteers
- 1,500 people
- Sponsor
- Diagram B.V.
Gastrointestinal Bleeding
Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding
This double-blind, randomized trial aims to evaluate whether uninterrupted anti-platelet therapy (clopidogrel) will increase the risk of bleeding associated with removal of polyp during colonoscopy in patients with coronary…
- Trial name
- NCT01806090
- Testing
- clopidogrel
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Chinese University of Hong Kong
Coronary Artery Disease
STEEL Percutaneous Coronary Intervention
The principal hypothesis of this study is that two different maintenance regimens of ticagrelor are safe, tolerable and associated with significant inhibition of erythrocyte adenosine reuptake compared to clopidogrel in patients…
- Trial name
- STEEL-PCI (NCT02327624)
- Testing
- Clopidogrel, Ticagrelor 60, Ticagrelor 90
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Myocardial Infarction
Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Activity in Myocardial Infarction (MI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI)
In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogrel and ticagrelor 180 mg loading dose will…
- Trial name
- NCT03613857
- Testing
- Clopidogrel, Ticagrelor 90mg
- Where
- Egypt
- Volunteers
- 1,022 people
- Sponsor
- Cairo University
Coronary Artery Disease
The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease
This study is being conducted to determine if smoking will influence the platelet aggregation inhibition ability of clopidogrel and prasugrel.
- Trial name
- NCT01260584
- Testing
- Prasugrel, Clopidogrel
- Where
- 3 sites in United States
- Volunteers
- 110 people
- Sponsor
- Daiichi Sankyo
Drug Interaction
Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects
This study is being conducted to test the hypothesis that coadministration of clopidogrel with DS-1040b will be safe and well tolerated.
- Trial name
- NCT02560688
- Testing
- DS-1040b, Clopidogrel
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Acute Coronary Syndrome, Myocardial Ischemia
Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management
The purpose of this study is to assess safety and efficacy of Ticagrelor versus Clopidogrel in Asian/KOREAn patients with acute coronary syndromes intended for invasive management.
- Conditions
- Acute Coronary Syndrome, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases
- Trial name
- TICA KOREA (NCT02094963)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 10 sites in South Korea
- Volunteers
- 800 people
- Sponsor
- Seung-Jung Park
Angina, Stable
Method of Clopidogrel Pre-treatment Undergoing Conventional Coronary Angiogram in Angina Patients
The study included 511 patients who underwent PCI because of angina during 2010-2011 at three Korean hospitals. Clopidogrel-naïve patients received either a loading dose (LD; 600 mg at 2-24 h before the procedure) or routine…
- Trial name
- MECCA (NCT03759067)
- Testing
- clopidogrel 75mg, Clopidogrel 300 mg, clopidogrel 600mg
- Volunteers
- 511 people
- Sponsor
- Korea University Anam Hospital
Secondary Prevention, Stroke
Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)
To investigate the risk of major bleeding (including gastrointestinal and intracranial bleeding episodes) among new users of low-dose acetylsalicylic acid (ASA) in clinical practice
- Conditions
- Secondary Prevention, Stroke, Ischemic Heart Disease, Coronary Heart Disease
- Trial name
- EPISAT (NCT02550717)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465), Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs
- Where
- United Kingdom
- Volunteers
- 398,158 people
- Sponsor
- Bayer
Major Depressive Disorder
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect…
- Trial name
- NCT01263093
- Testing
- Clopidogrel, LY2216684
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
HIV, Cardiovascular Diseases
Antiplatelet Therapy in HIV
The proposed study will add to the growing understanding of platelet activity and platelet inhibition in subjects with HIV. It will examine the relationship between platelet activity and its inhibition by antiplatelet therapy…
- Conditions
- HIV, Cardiovascular Diseases, Inflammation
- Trial name
- NCT02559414
- Testing
- Aspirin, Clopidogrel
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- NYU Langone Health
Acute Coronary Syndrome, Percutaneous Coronary Intervention
A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk
In patients with heart attacks, the treatment of choice is to restore blood flow with percutaneous coronary intervention (PCI) (use of stents (metal meshes) to open blockages).
- Trial name
- RAPID MANAGE (NCT02044146)
- Testing
- Ticagrelor, Prasugrel, Clopidogrel
- Where
- 2 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Platelet Dysfunction
clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad
The aim of this study was to determine the prevalence of clopidogrel resistance among a selected group of patients undergoing elective percutaneous coronary intervention and to observe whether there was any south-Asian…
- Trial name
- POINT (NCT03667066)
- Testing
- Clopidogrel
- Where
- Trinidad and Tobago
- Volunteers
- 40 people
- Sponsor
- The University of The West Indies
Myocardial Infarction
Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)
Although the optimal duration of clopidogrel (an anti-platelet agent) therapy has been established after bare metal stent implantation in the blood vessels of the heart, there is lack of consensus regarding the optimal duration…
- Trial name
- SCORE (NCT00781573)
- Testing
- Clopidogrel
- Where
- 3 sites in United States, Greece and 1 more
- Volunteers
- 167 people
- Sponsor
- North Texas Veterans Healthcare System
Severe Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation
Platelet Reactivity After TAVI: A Multicenter Pilot Study
A high platelet reactivity in patients with severe symptomatic Aortic Stenosis (AS) selected for TAVI (Transcatheter aortic valve implantation) procedure has been demonstrated previously, and the use of double antiaggregation…
- Conditions
- Severe Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation, Transcatheter Aortic Valve Replacement
- Trial name
- REAC-TAVI (NCT02224066)
- Testing
- Ticagrelor 90 mg twice per day during three months following TAVI, Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI
- Where
- 7 sites in Spain
- Volunteers
- 65 people
- Sponsor
- Hospital de Meixoeiro
Atrial Fibrillation, Percutaneous Coronary Intervention
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate…
- Trial name
- NCT02164864
- Testing
- Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin
- Where
- 421 sites in United States, Argentina and 39 more
- Volunteers
- 2,725 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease
PROMUS Element Plus US Post-Approval Study
This study is designed to observe clinical outcomes in patients receiving the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System in routine clinical practice.
- Trial name
- NCT01589978
- Testing
- PROMUS Element Plus Coronary Stent System, Aspirin, P2Y12 antagonist
- Where
- 52 sites in United States
- Volunteers
- 2,681 people
- Sponsor
- Boston Scientific Corporation
Vascular Surgery Patient With PAD / Carotid Stenosis
Perioperative Aspirin Response in Patients Undergoing Vascular Surgery
Reduced antiplatelet activity (low response (LR)/high on-treatment platelet reactivity (HPR)) of aspirin (ALR) or clopidogrel (CLR) is associated with an increased risk of thromboembolic events.
- Trial name
- NCT03587324
- Testing
- Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).
- Where
- Germany
- Volunteers
- 176 people
- Sponsor
- St. Josef Hospital Bochum